Said shares are to be distributed, subject to various regulatory filings with FINRA and SEC. All shareholders will be sent an Information Statement, which will be posted on Pink Sheets. The Information Statement will address most questions shareholders may have.
Nanoregen's audited financials for the prior years will be posted on Pink Sheets as well.
This reorganization is expected to enable Nanoregen to raise up to $5 million for further development and trials for Nanoregen’s new products. Nanoregen, Inc. will be headed by new management team that is currently being assembled.
TGI has retained law firm OFSINK, LLC (www.golawintl.com)
Olagenesis Corp. is developing Bone Marrow Mononuclear Cell (BMCC) transplant therapy for the treatment of severe acute and chronic cardiac disease, and has secured worldwide commercialization rights from the University of Hannover, Hannover, Germany to use BMCCs for such indications. Olagenesis is planning international, multi-center phase III clinical trials for the use of BMCCs to treat severe acute myocardial infarction. Phase II clinical studies have been successfully completed by the University of Hannover.
About TGI Solar
TGI SOLAR POWER GROUP INC. (www.tgisolar.com)
Safe Harbor Statements under the Private Securities Litigation Reform Act of 1965: Those statements contained herein which are not historical are forward-looking statements, and as such, are subject to risks and uncertainties that could cause actual operating results to materially differ from those contained in the forward-looking statements. Such statements include, but are not limited to, certain delays that are beyond the company's control, with respect to market acceptance of new technologies, or product delays in the testing and evaluation of products, and other risks, as detailed in the company's periodic filings with the Securities and Exchange Commission.